Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: CARPACCIO (CARboplatin PAClitaxel Cetuximab IO Immuno-oncology)

NCT06725368 is registered in ClinicalTrials.gov with Centre Paul Strauss as lead sponsor.

NCT NCT06725368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06725368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: CARPACCIO (CARboplatin PAClitaxel Cetuximab IO Immuno-oncology)
Lead sponsor
Centre Paul Strauss
Phase
Phase 2
Overall status
Recruiting
Start date
January 24, 2025
Completion date
January 31, 2032
Enrollment
46 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer